Trial · NCT01337986
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Per protocol analysis | LogMAR Score | MEAN |
| PRIMARY | Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Per protocol analysis | letters | MEAN |
| PRIMARY | Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1 | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Intent To Treat Population, scores from morning and afternoon were averaged. | 5% Contrast LogMAR Score | MEAN |
| SECONDARY | Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Percentages of eyes that improved | NUMBER | |
| SECONDARY | Percentage of Eyes That Improved by One-line (5 Letters) | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Proportion as the Percent of Eyes Improved by 1 Line | Percent of Eyes | NUMBER |
| SECONDARY | Visual Evoked Potential P100 Latency Per Treatment Arm | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | per protocol | milliseconds | MEAN |
| SECONDARY | Odds Ratio Quartile of Visual Field Index | Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2) | Visual Field Index % of normal vision | MEAN | |
| SECONDARY | Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100). | Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2) | per protocol | FM100 Total Error Score | MEAN |
| SECONDARY | Dalfampridine Effect on Quality of Life Change From Baseline. | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | NEI VFQ percentage | MEDIAN | |
| SECONDARY | Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | per protocol | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity | Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8) | Intent To Treat Population, scores from morning and afternoon were averaged. | letters | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01337986/outcomes